Treatment News : Once-a-Month HIV Meds Show Promise in Early Trial

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 17, 2013

Once-a-Month HIV Meds Show Promise in Early Trial

A pair of long-acting HIV antiretrovirals (ARVs) maintained adequate blood levels and exhibited a promising safety profile when given to HIV-negative participants in an early trial, aidsmap reports. Investigators tested the safety and pharmacokinetics of an injectable nanosuspension of the investigational integrase inhibitor GSK1265744 as well as TMC278-LA, which is a long-acting formulation of Janssen’s non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine). They presented their findings of this Phase I trial of 47 participants at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

A nanosuspended drug exists in tiny crystals that are suspended in liquid, leading to a more drawn-out period during which the drug is active within the body. Their less-frequent dosing is of particular interest for researchers for their use in improving adherence to ARVs, as well as for their use as a pre-exposure prophylaxis (PrEP) HIV prevention drug regimen among people at high risk for contracting the virus.

The study participants all began with two weeks of 30 milligrams per day of oral GSK1265744 to test that drug’s safety and tolerability. Then, after a weeklong gap period, they received one injection of 800 mg of the drug. Next, they were randomly divided into four treatment arms, which then received a respective:

  1. Injections of 200 mg of GSK1265744 at weeks 4, 8 and 12.
  2. Injections of 200 mg of GSK1265744 at weeks 4, 8 and 12, as well as 1,200 mg of TMC278-LA at week 8 and 900 mg at week 12.
  3. Injections of 400 mg of GSK1265744 at weeks 4, 8 and 12, as well as 1,200 mg of TMC278-LA at week 8 and 600 mg at week 12.
  4. One injection of GSK1265744 at week 12.

Ten participants dropped out of the trial, seven of them during the oral lead-in part of the trial and three others during the injection part.

In each of the treatment arms, the drugs reached a therapeutic level within three days. Both of them remained at high levels for a long period of time—well above 90 percent of the target concentration—and then dropped off slowly.

The drugs proved safe and well-tolerated, with one participant leaving the study during the lead-in phase because of dizziness and another leaving during the injection phase because of rash. Headache was the most common side effect.

To read the aidsmap story, click here.

To read the conference abstract, click here.

Search: HIV, long-acting antiretrovirals, aidsmap, nanosuspension, GSK1265744, TMC278-LA, Edurant, rilpivirine, 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, IAS 2013.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 1 (of 1 total)    

Alabi JO, Warri-Nigeria, 2013-07-25 14:08:43
These prospective pre-exposure ARV candidates may not present the same plasma profile in the presence of the HIV. I suggest that the trial should be done in HIV-positive individuals.

comments 1 - 1 (of 1 total)    


[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.